SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYTO
CYTO 0.0879-13.4%Aug 11 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ge who wrote (7177)4/7/1998 9:14:00 PM
From: squetch   of 8116
 
The results you speak of, making money, have lead to a secondary benefit for BTGC. That benefit is publicity in the form of SP coverage which was sent out at least all the Fidelity brokerage people, and Individual Investor mag coverage. Plus the added benefit of being "one of the few biotechs making any money."

BTGC's product revs were 11 mill, 21mill, 40.4mill, and 53.7 mill in 94, 95, 96, and 97 respectively. In 94 the range is ~2 to 6 by eyeball. Respectfully ge, I don't see BTGC today as a good comparison to CYTO tomorrow.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News